Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease

BACKGROUND: Sitafloxacin (STFX) exhibits potent activity against Mycobacterium avium complex (MAC) in both in vitro and in vivo experiments. However, limited data are available for the clinical efficacy and adverse effects of STFX and the susceptibility of refractory MAC lung disease (MAC-LD) to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Asakura, Takanori, Suzuki, Shoji, Fukano, Hanako, Okamori, Satoshi, Kusumoto, Tatsuya, Uwamino, Yoshifumi, Ogawa, Takunori, So, Matsuo, Uno, Shunsuke, Namkoong, Ho, Yoshida, Mitsunori, Kamata, Hirofumi, Ishii, Makoto, Nishimura, Tomoyasu, Hoshino, Yoshihiko, Hasegawa, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519390/
https://www.ncbi.nlm.nih.gov/pubmed/31111076
http://dx.doi.org/10.1093/ofid/ofz108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519390/
https://www.ncbi.nlm.nih.gov/pubmed/31111076
http://dx.doi.org/10.1093/ofid/ofz108

Ejemplares similares